Organoid-based Functional Precision Therapy for Advanced Breast Cancer

The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).

Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w

1000-1250mg/m2, PO, bid, days1-14, q3w

800-1200mg/m2, IV, days 1, 8, q3w

20-35mg/m2, IV, days 1 and 8, q3w

1.4mg/m2, IV, days 1 and 8, q3w

Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w

Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w

30mg/m2, IV, once per day on days 1-5, q3w

5.4mg/kg, IV, q3w

10mg/kg, IV, days 1 and 8, q3w